PT-141 – 10mg
From the USA.
No questions asked return policy.
Independent Lab Testing
Purity is verified. Click here for more information.
Comodo SSL secure checkout.
Fast and Discrete Shipping
Same day USPS 1-3 day Priority Mail shipping for all orders placed before 6pm EST Monday through Friday.
Discount per Quantity
|Quantity||2 -3||4 -9||10 +|
- Reviews (3)
PT-141 is a non-selective agonist of all the melanocortin receptors 1, 3, 4 and 5. Activation of the melanocortin 4 receptor stimulates libido to a very significant degree.
|Names:||PT-141, PT 141, Bremelanotide|
|Unit Size:||10mg vial|
|CoA:||Certificate of Analysis for LOT#: 82939|
|Storage:||Freeze until reconstitution. Refrigerate after reconstitution.|
|Terms:||Research use only.|
PT-141: a melanocortin agonist for the treatment of sexual dysfunction.
An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.
Bremelanotide: an overview of preclinical CNS effects on female sexual function.
Melanocortins in the treatment of male and female sexual dysfunction.
Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.
Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study.
Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.
Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.
Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.
Melanocortin receptors, melanotropic peptides and penile erection.